[The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the Priority Index in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.]

[The struggle against anxiety disorders and symptoms of anxiety is as old as the history of human healing. The development of anxiolytics has constituted an important field of pharmacology from the very beginning. The appearance of benzodiazepines and high-potential benzodiazepines, developed as a later evolution of the former compounds, is considered a milestone in this battle. Today alprazolam is their most widely-used representative that can be considered a golden standard. Besides its agent, the formulation of the drug is also significant, as it helps in the administration, absorption and bioavailability of the agent and even for the establishment of good compliance. Nowadays we can witness the development of medicine families containing the same active ingredient and consisting of various products. In the case of alprazolam, we can welcome a new member of the family following the immediate-release tablets and the extended-release tablets. The aim of this paper is the introduction of the new member of the alprazolam family: the sublingual tablet.]